Our findings point to two clinical considerations: a potential rationale for a more permissive attitude toward biologic therapy (including anti-TNF agents) in patients with heart failure, and the need for particular caution when contemplating azathioprine in the same setting. This evidence concerns the gene TNF and heart failure.